← Issue №14/ week of Oct 4, 2026/IBD

Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn's disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD retrospective · n=50 · Oct 1, 2026 · Inflamm Bowel Dis · IF 4.5

Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn's disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN.

New evidenceCrohn's diseaseperianal diseaseustekinumabpediatric
Clinical takeawayConsider ustekinumab as a potential therapeutic option for pediatric perianal Crohn's disease patients who fail anti-TNF therapy, recognizing its investigational role in this population.
What it foundUstekinumab achieved clinical remission in 48% (23/48) and radiological remission in 30% (13/43) of pediatric perianal Crohn's disease patients at 1 year compared to baseline.
ContextThis study supports ustekinumab's potential role in pediatric perianal Crohn's disease, particularly in anti-TNF-exposed patients, where remission rates approach 50% clinically and 30% radiologically at 1 year compared to baseline.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Orlin I … Rinawi F · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues